AN2 Therapeutics (ANTX) Return on Capital Employed (2022 - 2026)

AN2 Therapeutics (ANTX) has 5 years of Return on Capital Employed data on file, last reported at 53.68% in Q1 2026.

• On a quarterly basis, Return on Capital Employed changed N/A year-over-year to 53.68% in Q1 2026; TTM through Mar 2026 was 53.68%, a N/A change from a year earlier, with the FY2025 full-year figure at 55.8%, down 181.0% from the prior year.
• Return on Capital Employed for Q1 2026 stood at 53.68%, up from 68.21% in the prior quarter.
• Over the last five years, Return on Capital Employed for ANTX reached as high as 28.03% in Q2 2022 and fell as low as 72.0% in Q3 2024.
• Historically, Return on Capital Employed has averaged 52.59% across 5 years, with a median of 55.22% in 2023.
• Across the five-year window, Return on Capital Employed sank 3982 bps in 2023 and tumbled 112 bps in 2025, its largest moves.
• Year by year, Return on Capital Employed stood at 42.65% in 2022, then dropped by 23 bps to 52.66% in 2023, then decreased by 27 bps to 67.09% in 2024, then declined by 2 bps to 68.21% in 2025, then gained by 21 bps to 53.68% in 2026.
• Per Business Quant data, the three most recent Return on Capital Employed figures were 53.68% in Q1 2026, 68.21% in Q4 2025, and 67.09% in Q4 2024.